Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CNR1 | P21554 | 2/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223891 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL1327631 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL12475206 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL851866 | 0.85 | SMN1; SMN2 (0.78) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL28795980 | 0.84 | RAB9A (0.57) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL289112 | 0.83 | SMN1; SMN2 (0.93) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL4243016 | 0.83 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL3065347 | 0.83 | CYP1A2 (0.75) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL3068544 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1MAPTGAANPC1 | |
| Hydrochloric Acid SCHEMBL11388173 | 0.82 | CYP1A2 (0.73) | SMN1; SMN2ALDH1A1MAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638737-A | Macrocyclic compounds and their use in medicine | 广东东阳光药业股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-107089993-B | Hypolipidemic activity bamboo-cypress lactone compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-07-09 | — | — | CN | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3190109-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2440550-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-11-10 | — | — | US | disclosed |
| US-9434722-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-09-06 | — | — | US | disclosed |
| CN-102532123-B | Thiazole-5-methanamide compound and method for making thereof and pharmaceutical composition and purposes | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-03-09 | — | — | CN | disclosed |
| CN-100363348-C | PgD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2008-01-23 | — | — | CN | disclosed |
| CN-101018770-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| CN-1720047-A | PgD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2006-01-11 | — | — | CN | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050222160-A1 | Thiazole derivatives as phosphodiesterase iv inhibitors | MERCK PATENT GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| CN-1662529-A | Thiazole derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2005-08-31 | — | — | CN | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | SMN1; SMN2 81/4885ALDH1A1 2404/4885MAPT 2/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | SMN1; SMN2 4770/4885ALDH1A1 1599/4885MAPT 4208/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | SMN1; SMN2 4803/4885ALDH1A1 2039/4885MAPT 4401/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | SMN1; SMN2 80/4885ALDH1A1 2395/4885MAPT 2/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | SMN1; SMN2 81/4885ALDH1A1 2404/4885MAPT 2/4885 |
| US-20050222160-A1 | Thiazole derivatives as phosphodiesterase iv inhibitors | PDE3B, PDE4B, PDE4A | SMN1; SMN2 3019/4885ALDH1A1 1542/4885MAPT 4552/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | SMN1; SMN2 1271/4885ALDH1A1 1081/4885MAPT 553/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | SMN1; SMN2 4763/4885ALDH1A1 1663/4885MAPT 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.